Back to Trades
Sell4
REVVITY, INC.
RVTY
Total Value
$15.5M
Net $2.6M sold
Sales
$2.6M
5 transactions
Company Information
- Company Name
- REVVITY, INC.
- Ticker Symbol
- RVTY
- CIK
- 0000031791
Insider Information
- Name
- Singh Prahlad R.
- Role
- Insider
- Location
- WALTHAM, MA
Filing Details
- Filing Date
- Feb 6, 2026
- Transaction Date
- Feb 4, 2026
- Accession Number
- 0001193125-26-041158
- Form Type
- 4
- Net Trading Amount
- -$2.6M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Feb 4, 2026 | Common Stock | 3,421 | $101.13 | Tax Withholding | $346.0K |
| Feb 4, 2026 | Common Stock | 26,796 | — | Grant/Award | — |
| Feb 5, 2026 | Common Stock | 25,525 | $92.09 | Exercise | $2.4M |
| Feb 5, 2026 | Common Stock | 1,307 | $99.02 | Sale | $129.4K |
| Feb 5, 2026 | Common Stock | 12,186 | $99.55 | Sale | $1.2M |
| Feb 5, 2026 | Common Stock | 7,885 | $100.63 | Sale | $793.5K |
| Feb 5, 2026 | Common Stock | 3,079 | $101.45 | Sale | $312.4K |
| Feb 5, 2026 | Common Stock | 1,068 | $102.52 | Sale | $109.5K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Feb 4, 2026 | Derivative | 76,647 | $103.39 | Grant/Award | $7.9M |
| Feb 5, 2026 | Derivative | 25,525 | $92.09 | Exercise | $2.4M |
Footnotes
- (F1)The vesting schedule for the restricted stock unit grant to the Reporting Person included in the Form 4 filed on February 6, 2025 was incorrectly reported due to administrative error. The restricted stock unit grant included in that Form 4 is scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant.
- (F2)These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 4, 2025, as required by the Reporting Person's Restricted Stock Unit Agreement.
- (F3)Shares are time-based restricted stock units that are scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant.
- (F4)The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.
- (F5)The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $98.98 to $99.07. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- (F6)The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $99.10 to $100.08. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- (F7)The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $100.10 to $101.09. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- (F8)The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $101.12 to $101.93. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- (F9)The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $102.18 to $103.03. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- (F10)Securities held in an irrevocable trust for the sole benefit of the Reporting Person's children. The Reporting Person's spouse is the trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- (F11)This option is scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant.
- (F12)This option became exercisable in three equal annual installments beginning on February 5, 2020, which was the first anniversary of the date on which the option was granted.